Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 2019, 5878960

Immunomodulation of CXCL10 Secretion by Hepatitis C Virus: Could CXCL10 Be a Prognostic Marker of Chronic Hepatitis C?


Immunomodulation of CXCL10 Secretion by Hepatitis C Virus: Could CXCL10 Be a Prognostic Marker of Chronic Hepatitis C?

Silvia Martina Ferrari et al. J Immunol Res.


Chemokine (C-X-C motif) ligand (CXCL)10 and other CXCR3 chemokines are involved in the pathogenesis of acute and "chronic hepatitis C virus (HCV) infection" (CHC). Here, we review the scientific literature about HCV and CXCL10. The combination of circulating CXCL10 and single nucleotide polymorphisms (SNPs) in IL-28B can identify patients with acute HCV infection most likely to undergo spontaneous HCV clearance and those in need of early antiviral therapy. In CHC, the HCV and intrahepatic interferon- (IFN-) γ drive a raised CXCL10 expression by sinusoidal endothelium and hepatocytes, thereby inducing the recruitment of CXCR3-expressing T cells into the liver; thus, CXCL10 plays an important role in the development of necroinflammation and fibrosis. Increased CXCL10 was significantly associated with the presence of active vasculitis in HCV-associated cryoglobulinemia, or with autoimmune thyroiditis in CHC. Pretreatment CXCL10 levels are predictive of early virological response and sustained virological response (SVR) to IFN-α and ribavirin and may be useful in the evaluation of candidates for therapy. The occurrence of SNPs adjacent to IL-28B (rs12979860, rs12980275, and rs8099917), and CXCL10 below 150 pg/mL, independently predicted the first phase viral decline and rapid virological response, which in turn independently predicted SVR. Directly acting antiviral agents-mediated clearance of HCV is associated with the loss of intrahepatic immune activation by IFN-α, associated by decreased levels of CXCL10. In conclusion, CXCL10 is an important marker of HCV clearance and successful therapy in CHC patients. Whether CXCL10 is a novel therapeutic target in CHC will be evaluated.

Conflict of interest statement

The authors have nothing to declare.

Similar articles

See all similar articles


    1. Lemoine M., Thursz M. Hepatitis C, a global issue: access to care and new therapeutic and preventive approaches in resource-constrained areas. Seminars in Liver Disease. 2014;34(1):089–097. doi: 10.1055/s-0034-1371082. - DOI - PubMed
    1. Maheshwari A., Ray S., Thuluvath P. J. Acute hepatitis C. The Lancet. 2008;372(9635):321–332. doi: 10.1016/S0140-6736(08)61116-2. - DOI - PubMed
    1. Patel K., Muir A. J., McHutchison J. G. Diagnosis and treatment of chronic hepatitis C infection. British Medical Journal. 2006;332(7548):1013–1017. doi: 10.1136/bmj.332.7548.1013. - DOI - PMC - PubMed
    1. Rosen H. R. Chronic hepatitis C infection. The New England Journal of Medicine. 2011;364(25):2429–2438. doi: 10.1056/NEJMcp1006613. - DOI - PubMed
    1. Calvaruso V., Craxì A. 2011 European Association of the study of the liver hepatitis C virus clinical practice guidelines. Liver International. 2012;32(Supplement 1):2–8. doi: 10.1111/j.1478-3231.2011.02703.x. - DOI - PubMed